Gabapentin Capsule
Product Images NDC 82868-073

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 82868-073). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (82868 073 30 Rev A 03 25 Nhc)

Label for Gabapentin Capsules USP 300 mg by Northwind Health Company, LLC. The label indicates a package containing 30 oral capsules, with storage instructions and pharmacy repackaging details. It includes dosage form, strength, quantity, and regulatory reminders like Rx only and storage temperature.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 01)

Chemical structure diagram of gabapentin, showing its molecular arrangement including a cyclohexane ring and functional groups with amino and carboxyl components.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 02)

A line graph showing mean pain scores over an 8-week period for two groups: placebo and gabapentin (3600 mg/day). The x-axis represents weeks, starting at baseline and continuing through week 8. The y-axis measures mean pain score on a scale from 0 to 10. The graph indicates a 4-week dose titration period followed by a 4-week fixed dose period, with gabapentin showing a decreasing trend in mean pain score over time compared to placebo, which remains relatively stable.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 03)

Line graph showing mean pain score over 7 weeks for placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day groups. The x-axis represents weeks from baseline to week 7, and the y-axis shows mean pain scores on a scale from 0 to 10. The graph indicates dosage titration during the first 3 weeks followed by a 4-week fixed dose period.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 04)

A bar chart comparing the proportion of responders with at least 50% reduction in pain score at endpoint in two controlled postherpetic neuralgia (PHN) studies. Study 1 shows a 12% response for placebo (PBO) and 29% for gabapentin (GBP) 3600 mg. Study 2 reports 14% for placebo and 32% and 34% for GBP 1800 mg and 2400 mg respectively. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Image (B7e57ea4 D985 4167 8c2d 716cf3c60114 05)

A scatter plot showing the percentage difference versus daily dose (mg) of gabapentin for three studies labeled a, b, and c. The x-axis represents daily doses of 600, 900, 1200, and 1800 mg, and the y-axis shows percentage differences ranging from 2% to 22%. Study a is represented by black squares, Study b by gray squares, and Study c by white squares.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.